Literature DB >> 25814591

Complete Genome Sequence of the Hypervirulent Bacterium Clostridium difficile Strain G46, Ribotype 027.

Tom Gaulton1, Raju Misra2, Graham Rose1, Primo Baybayan3, Richard Hall3, Jane Freeman4, Jane Turton1, Steve Picton3, Jonas Korlach3, Saheer Gharbia1, Haroun Shah1.   

Abstract

Clostridium difficile is one of the leading causes of antibiotic-associated diarrhea in health care facilities worldwide. Here, we report the genome sequence of C. difficile strain G46, ribotype 027, isolated from an outbreak in Glamorgan, Wales, in 2006.
Copyright © 2015 Gaulton et al.

Entities:  

Year:  2015        PMID: 25814591      PMCID: PMC4384131          DOI: 10.1128/genomeA.00073-15

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Clostridium difficile has emerged in recent years as a common cause of infectious antibiotic-associated diarrhea within health care facilities worldwide. It is a Gram-positive anaerobic prokaryote, notorious for being multidrug-resistant and causing C. difficile infections (CDIs). It can produce a variety of virulence factors that lead to intestinal colonization and disease; for example, it is known to express up to three toxins, toxin A (TcdA), toxin B (TcdB), and, less commonly, binary toxin (CDT) (1), which contribute to the clinical spectrum of the disease, ranging from mild nonspecific diarrhea to severe pseudomembranous colitis (PMC) and paralytic ileus (2, 3). C. difficile has been linked to antibiotic use for decades. During the 1970s, increases in CDIs were attributed to clindamycin use, in the 1980s, to cephalosporin and penicillin use, and in the 2000s, to fluoroquinolone use (4). Careful antimicrobial stewardship has been used to limit CDI risk, but it remains a significant burden on health care systems (5). Therapeutic options for CDI treatment remain limited to metronidazole and vancomycin, with the recent addition of fidaxomicin (6). Worryingly, despite treatment, approximately 20 to 30% of patients suffer from recurrence (7). The genomes for several 027 ribotyped strains have been sequenced; however, very few have been sequenced and assembled to completion. We report here the complete genome of C. difficile strain G46. This strain was isolated from an outbreak in Glamorgan, Wales, in 2006 and is representative of the “hypervirulent” ribotype 027 strains. Sequencing was performed by Pacific Biosciences (Menlo Park, CA) using the PacBio RS II system. A total of 146,976 filtered subreads were used for the assembly, from three single-molecule real-time (SMRT) cells. The read lengths varied from 50 to 63,997 bases in length and were assembled using the HGAP long-read assembler. A single circularized chromosomal contig was generated, 4,189,317 bases in length (29% G+C content), and was annotated using the Prokka annotation pipeline (8). We annotated 3,811 protein coding sequences, which encompassed 84.1% of the genome. Of the 3,811 annotated sequences, 706 encoded hypothetical or putative proteins. We identified 125 tRNA-coding, 5 rRNA-coding operons, and 176 signal peptides. In parallel, the epigenome was elucidated, revealing many modifications borne from DNA methylation (9). Comparisons with the well-characterized C. difficile strain R20291, ribotype 027, revealed high sequence similarity (99.99%). C. difficile G46 possessed both the PaLoc operon (19.6 kb) and the binary toxin operon (6.2 kb), sharing 100% sequence similarity with strain R20291. Like strain R20291, strain G46 encodes for variety of antibiotic resistance features, such as point mutations in the DNA gyrase genes, which cause resistance to fluoroquinolones (10). The MICs of moxifloxacin (fluoroquinolone) corroborated the genomic prediction, demonstrating high resistance, with an MIC of 16 mg/liter (an MIC of 4 mg/liter indicates resistance).

Nucleotide sequence accession numbers.

The genome sequence of C. difficile strain G46 has been deposited in the ENA under the accession no. CDND00000000. The version described in this paper is the first version, CDND01000000. The methylation motifs were deposited in REBASE (http://rebase.neb.com/rebase/refs/18866.html).
  10 in total

1.  Pathogenic C difficile is here (and everywhere) to stay.

Authors:  Cirle A Warren; Richard L Guerrant
Journal:  Lancet       Date:  2011-01-01       Impact factor: 79.321

Review 2.  Alternative treatments for Clostridium difficile disease: what really works?

Authors:  Lynne V McFarland
Journal:  J Med Microbiol       Date:  2005-02       Impact factor: 2.472

3.  Clostridium difficile and the disease it causes.

Authors:  Torbjörn Norén
Journal:  Methods Mol Biol       Date:  2010

4.  Prokka: rapid prokaryotic genome annotation.

Authors:  Torsten Seemann
Journal:  Bioinformatics       Date:  2014-03-18       Impact factor: 6.937

Review 5.  Pseudomembranous colitis in children.

Authors:  Itzhak Brook
Journal:  J Gastroenterol Hepatol       Date:  2005-02       Impact factor: 4.029

6.  Direct detection of DNA methylation during single-molecule, real-time sequencing.

Authors:  Benjamin A Flusberg; Dale R Webster; Jessica H Lee; Kevin J Travers; Eric C Olivares; Tyson A Clark; Jonas Korlach; Stephen W Turner
Journal:  Nat Methods       Date:  2010-05-09       Impact factor: 28.547

Review 7.  Epidemiology of Clostridium difficile infection.

Authors:  Daryl D Depestel; David M Aronoff
Journal:  J Pharm Pract       Date:  2013-10

Review 8.  Interventions to improve antibiotic prescribing practices for hospital inpatients.

Authors:  Peter Davey; Erwin Brown; Esmita Charani; Lynda Fenelon; Ian M Gould; Alison Holmes; Craig R Ramsay; Philip J Wiffen; Mark Wilcox
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

9.  Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

Authors:  Derrick W Crook; A Sarah Walker; Yin Kean; Karl Weiss; Oliver A Cornely; Mark A Miller; Roberto Esposito; Thomas J Louie; Nicole E Stoesser; Bernadette C Young; Brian J Angus; Sherwood L Gorbach; Timothy E A Peto
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

10.  Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium.

Authors:  Richard A Stabler; Miao He; Lisa Dawson; Melissa Martin; Esmeralda Valiente; Craig Corton; Trevor D Lawley; Mohammed Sebaihia; Michael A Quail; Graham Rose; Dale N Gerding; Maryse Gibert; Michel R Popoff; Julian Parkhill; Gordon Dougan; Brendan W Wren
Journal:  Genome Biol       Date:  2009-09-25       Impact factor: 13.583

  10 in total
  4 in total

Review 1.  Diversity and Evolution in the Genome of Clostridium difficile.

Authors:  Daniel R Knight; Briony Elliott; Barbara J Chang; Timothy T Perkins; Thomas V Riley
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

2.  Higher genome variability within metabolism genes associates with recurrent Clostridium difficile infection.

Authors:  Maria Kulecka; Edyta Waker; Filip Ambrozkiewicz; Agnieszka Paziewska; Karolina Skubisz; Patrycja Cybula; Łukasz Targoński; Michał Mikula; Jan Walewski; Jerzy Ostrowski
Journal:  BMC Microbiol       Date:  2021-01-28       Impact factor: 3.605

3.  The First Two Clostridium difficile Ribotype 027/ST1 Isolates Identified in Beijing, China-an Emerging Problem or a Neglected Threat?

Authors:  Jing-Wei Cheng; Meng Xiao; Timothy Kudinha; Zhi-Peng Xu; Xin Hou; Lin-Ying Sun; Li Zhang; Xin Fan; Fanrong Kong; Ying-Chun Xu
Journal:  Sci Rep       Date:  2016-01-07       Impact factor: 4.379

4.  Use of single molecule sequencing for comparative genomics of an environmental and a clinical isolate of Clostridium difficile ribotype 078.

Authors:  Katherine R Hargreaves; Anisha M Thanki; Bethany R Jose; Marco R Oggioni; Martha R J Clokie
Journal:  BMC Genomics       Date:  2016-12-13       Impact factor: 3.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.